iMSC cells to prevent severe graft-versus-host disease after transplant
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old
- You have had a stem cell transplant from another person (allogeneic) for a blood disease, and it has been 7 to 21 days since the transplant
- Your standard GvHD prevention medicines include a CNI (like tacrolimus or cyclosporine) and mycophenolate mofetil, with or without methotrexate and rabbit ATG
- A special blood test (MAP score) shows you are at increased risk for GvHD at day 7 or day 14 after transplant
- Your overall health is fairly good (ECOG score 0-2 and HCT-CI score 0-3)
- You do not have serious organ failure, active infections (like hepatitis B, C, HIV, or syphilis), or another cancer (except certain treated skin or cervical cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.